PubMed Health⌕ Search

Biomedical subjects

L Resegotti

Publications and source records attributed to L Resegotti.

At least 109 records · Page 6Linked to original sources
PubMedDate not supplied

Serum lactate dehydrogenase is an important risk determinant in acute lymphocytic leukemia.

Pretreatment serum total lactate dehydrogenase (LDH) activity was measured in 341 adult patients (greater than 15 years old) with acute lymphocytic leukemia (ALL) in order to assess its prognostic value. Failure, death during induction and remission were not related to LDH. In contrast, a negative and continuous relationship was found between LDH and relapse-free survival. Though LDH activity was significantly higher in cases with already established risk factors such as high WBC count, FAB L3 cytotype, mature B-cell phenotype, and central nervous system involvement, LDH was confirmed to be the strongest predictor of remission duration by multivariate analysis. This study provides a definitive confirmation of the negative prognostic value of LDH in adult ALL.

Adolescent↗
PubMedDate not supplied

Intensification in post-remission treatment of adult acute non lymphocytic leukemia.

In an attempt to reduce the risk of leukemic relapse, different post-remission intensifications based on high-dose Ara-C (HiDAC) and autologous bone marrow transplantation (ABMT) were evaluated in patients with acute non lymphocytic leukemia in first remission and compared as to response and toxicity. Between September, 1985 and May, 1987, 34 patients in complete remission were eligible for our study. Induction therapy consisted of one or two courses of daunorubicin (DNR) and Ara-C (schedule 3 + 7). Fourteen patients receiving intensive post-remission chemotherapy with DNR + Ara-C (schedule 2 + 5), HiDAC + DNR, and ABMT following pretransplant BAVC conditioning entered the first pilot study. A high toxicity was observed and only 5 of them completed the full treatment plan. Thus the second pilot study used a single post-remission intensive course with HiDAC + m-AMSA and ABMT following cyclophosphamide plus TBI or BAVC. This approach was more feasible. The preliminary results show the usefulness of intensive post-remission therapy: in fact, all patients but one who completed the treatment program are still in continuous complete remission. A large number of patients and a longer follow-up are required to draw final conclusions.

Adolescent↗
PubMedDate not supplied

[Immunological changes in diabetes mellitus. Study of lymphocyte populations].

In view of some data of the literature suggesting that immunological changes could play a role in the pathogensis of diabetes mellitus and of its complications, we carried out a study of the lymphocyte populations of 44 diabetic subjects by means of E, EA, EAC rosettes and membrane immunofluorescence. A quarter of the patients had decreased E rosettes: all of these had long-lasting, insulin-dependent, poorly controlled diabetes. Some of these patients had also increased membrane IgG globulins. In 5 patients with recent onset, insulin-independent diabetes, E rosettes were increased. No significant changes of EA and EAC rosettes were observed. These findings suggest that changes of lymphocyte populations do not play any role in the pathogenesis of diabetes, while these may be the consequence of the metabolic disorder and these may favour the onset of complications of the disease.

Adult↗
PubMedDate not supplied

[Immunity and neoplasms. Behavior of E rosette-forming lymphocytes in patients with malignant neoplasms].

The per cent and absolute figures of E rosette forming lymphocytes have been evaluated in the blood of normal subject and of patients with non-neoplastic diseases and with epithelial and lymphoreticular tumours. The percentage of rosetting lymphocytes was not affected by non-neoplastic diseases, whilst it was by tumours, especially by lymphoreticular ones. However differences were not statistically significant in view of the large dispersion of values. Absolute counts of rosetting lymphocytes displayed lesser variations. These findings are better explained by Schwartz's concept of immunoregulation than by Burnet's theory of immunosurveillance.

Adolescent↗
PubMedDate not supplied

[Immunopathological characteristics of the lymphocytes of chronic lymphocytic leukemia, fractionated on gradients of various densities].

Spontaneous rosettes and membrane immunofluorescence for the various classes of heavy and light immune globulin have been determined on lymphocyte subfractions obtained from the blood of 6 normal subjects and 16 patients with CLL by separation on gradients of various density. Whereas in the normal subject lymphocyte immunological features proved similar in all fractions, in CLL they presented significant differences from fraction to fraction, with the presence only in certain fractions of the lymphocyte peak with monoclonal membrane immune globulin and without peak coincidence for IgD and IgM, probably as a result of changes in the physico-chemical features of the lymphocytes occurring during maturation. All fractions presented a sizeable complement of lymphocytes not forming rosettes and without demonstrable membrane immune globulins. The correlation between the behaviour of membrane labels and lymphocyte morphology, stage, duration and course of the disease has been analysed. The variability in lymphocyte subfraction characteristics separable at different densities may explain discrepancies of findings in researches carried out in lymphocytes that separate only at gradient of density 1077.

Aged↗
PubMedDate not supplied

Serum erythropoietin level and marrow erythroid infiltration predict response to recombinant human erythropoietin in myelodysplastic syndromes.

BACKGROUND AND METHODS: In 38 patients with myelodysplastic syndromes (MDS) the values of serum erythropoietin were measured at diagnosis and compared with the haemoglobin level. A highly significant inverse relationship was found between these two parameters, suggesting that the physiologic mechanism of erythroid progenitor cell recruitment is preserved in MDS. Fourteen transfusion-dependent patients were treated with recombinant human erythropoietin at the dose of 150 U/Kg three times weekly for at least 2 months. RESULTS AND CONCLUSIONS: Under recombinant human erythropoietin, three patients became transfusion-independent and 5 had a transient decrease of their transfusion requirement. Two patients under prolonged treatment at the same dose of erythropoietin remain in complete remission after 12 and 15 months respectively. A direct relationship between response to erythropoietin treatment and degree of bone marrow erythroid hyperplasia, coupled to an inverse correlation between response to erythropoietin and baseline serum erythropoietin levels were noted. Based on these findings, recombinant human erythropoietin may represent an effective treatment modality for selected patients with MDS.

Aged↗
PubMedDate not supplied

Results of a low aggressivity chemotherapy regimen (CVP/CEB) in elderly Hodgkin's disease patients.

BACKGROUND: Hodgkin's disease (HD) after the age of 65 years is uncommon and there are no published data on chemotherapy regimens devised for elderly HD patients. PATIENTS AND METHODS: From 1990 to 1993, 25 elderly HD patients were treated with the CVP/CEB regimen: chlorambucil 6 mg/sqm p.o. days 1 through 7, vinblastine 6 mg/sqm i.v. on day 1, procarbazine 100 mg/sqm p.o. days 1 through 7, prednisone 30 mg/sqm p.o. days 1 through 7, cyclophosphamide 500 mg./sqm i.v. day 15, etoposide 70 mg/sqm i.v. day 15, bleomycin 10 mg/sqm i.v. day 15. Each course was repeated every 4 weeks. Stage I and II patients were treated with 3 courses followed by involved field radiotherapy, while more advanced stage patients received 6 courses and radiotherapy was limited to bulky areas. The results of the CVP/CEB regimen are retrospectively compared to those of 74 elderly patients treated between 1982 and 1989 and subdivided into the following 2 groups: 32 patients treated according to the same therapy used at that time in younger patients, and 42 patients given alternative low aggressivity or palliative treatment. RESULTS: CVP/CEB is a well-tolerated regimen, with only 1 (4%) toxic death and 2 (8%) protocol violations/interruptions. The CVP/CEB complete remission rate (73%) compares favorably with our previous groups of patients, mainly because of the lower toxic death rate. However, the CVP/CEB relapse-free survival rate is lower than that of patients treated with more aggressive conventional regimens (47% vs. 77%, p < 0.02). The CVP/CEB overall survival and event-free survival rates are 55% and 32%, respectively, and they are not statistically different from those of patients treated before 1990. CONCLUSIONS: CVP/CEB is a well-tolerated low toxicity regimen with a high CR rate. The relapse rate is high and event-free survival is comparable to that of patients treated conventionally. Our results suggest the need for individualized treatment criteria for older patients with HD.

Aged↗
PubMedDate not supplied

Significance of cell proliferation index in assessing histological prognostic categories in Hodgkin's disease. An immunohistochemical study with Ki67 and MIB-1 monoclonal antibodies.

BACKGROUND AND OBJECTIVE: In their review of the Rye histopathological classification of Hodgkin's disease, Bennett and coworkers have proposed that the nodular sclerosis (NS) type should be divided into two diagnostic categories on the basis of their clinical behaviour. In order to evaluate whether the proliferative activity of HD cells might correlate with histology in NS subtypes, we reviewed and re-evaluated cryostat and paraffin-embedded sections from 80 cases sent to our centre from 1986 to 1991. METHODS: In the present study, we investigated the growth cell fraction of 53 cases of Hodgkin's disease with nodular sclerosis by using Ki67 and MIB1 monoclonal antibodies to determine whether proliferative activity is associated with different pathological subtypes and prognostic categories. Eight cases with an interfollicular pattern and 19 with mixed cellularity were also investigated. The results in each group were compared to the others. RESULTS: The values of Ki67 and MIB1 were highly correlated (r = 0.88). In Hodgkin's disease with nodular sclerosis, two groups with significantly different growth fractions were morphologically identified: one with lymphocyte predominance and mixed cellularity subtypes, another composed of cases with variously extensive lymphocyte depletion. The figures were compared with those of interfollicular subtype, which fell into the first group, and of mixed cellularity type, in which the proliferative cell activity was significantly higher than in the second nodular sclerosis group. In all cases, Reed-Sternberg and Hodgkin cells accounted for the majority of the cell growth fraction, although a variable percentage of T-lymphocytes were also Ki67- or MIB1-positive. Taking the median value (15%) of MIB1 positive cells as a cut-off, a significant correlation (p = 0.05) was observed between MIB1 positivity and bulky disease, and a good trend (but not a significant relationship) between MIB1 and overall survival, disease-free survival, staging and the clinical response to therapy. INTERPRETATION AND CONCLUSIONS: Assessment of the growth cell fraction in Hodgkin's disease with different nodular sclerosis patterns provides biological support for the morphological reclassification of their degree of malignancy into two main groups with different impacts on the clinical parameters and a possible relation with the outcome of treatment.

Antibodies, Monoclonal↗